CHICAGO -- Incorporating the investigational, oral selective estrogen receptor degrader (SERD) camizestrant at the first sign of emerging ESR1 mutations extended the benefit of first-line therapy ...

Photopsia (brief flashes of light) was reported in 20.0% of camizestrant-treated patients, compared to 7.7% in the control group. These events were mostly mild and did not impair daily activities.

Photopsia: The perception of flashes or flickering lights in the visual field, often associated with retinal dysfunction. Acute Zonal Occult Outer Retinopathy Publication Trend.

Compr Ophthalmol Update. 2007;8(4):179-200. Dr. Matsumoto is affiliated with the Vitreous-Retina-Macula Consultants of New York, New York, NY, and the Department of Ophthalmology, Surugadai Nihon ...

Median progression-free survival (PFS) improved from 9.2 months for those who remained on the AI to 16 months with the switch to the next-generation oral SERD (adjusted HR 0.44, 95% CI 0.31-0.60 ...

Based on the results of the SERENA-6 Phase III trial, camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) has been granted Breakthrough Therapy Designation ...

CASE REPORT. A 56 year old white female emmetrope (20/20 both eyes) presented with photopsia secondary to posterior vitreous separation. Bilateral, thin (<0.5 mm), grey-white, granular but continuous, ...

Population-based data indicate that anterior uveitis constitutes roughly 50%-70% of all cases in the UK, with an overall prevalence estimated between 25 and 50 per 100,000 adults. Most affected ...

Cancer-associated retinopathy (CAR), a retinal photoreceptor degeneration disease, is characterised by photopsia and progressive visual loss, and is considered to be related to the presence of ...

The most common adverse effects of digoxin in the SNF setting are likely to be gastrointestinal disturbances (nausea, diarrhea, anorexia, abdominal discomfort), central nervous system disorders ...